| ID Source | ID |
|---|---|
| PubMed CID | 9918908 |
| CHEMBL ID | 421882 |
| CHEBI ID | 91864 |
| SCHEMBL ID | 4424095 |
| Synonym |
|---|
| CHEMBL421882 |
| HMS3269O03 |
| BRD-A75478957-001-01-6 |
| NCGC00167760-01 |
| SCHEMBL4424095 |
| n-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-l-valine |
| CHEBI:91864 |
| J-012917 |
| FT-0774322 |
| 2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid |
| Q27163657 |
| (2s)-2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " For this series of compounds, our objective was to systematically replace substituents appended to the biphenyl and alpha-position of 5 with structurally diverse functionalities to assess the effects these changes have on biological and pharmacokinetic activity." | ( Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. Dyer, RD; Hallak, H; Johnson, LL; Man, CF; O'Brien, PM; Ortwine, DF; Pavlovsky, AG; Picard, JA; Roth, BD; Sliskovic, DR, 2000) | 0.31 |
| Class | Description |
|---|---|
| biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
| organobromine compound | A compound containing at least one carbon-bromine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 50.1187 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0000 | 0.0000 | 1.2848 | 10.0000 | AID732015 |
| 72 kDa type IV collagenase | Homo sapiens (human) | Ki | 2.0000 | 0.0000 | 0.3466 | 3.0000 | AID107183 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 0.0000 | 0.0000 | 1.1484 | 10.0000 | AID732014 |
| Collagenase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0000 | 0.0000 | 0.7675 | 10.0000 | AID732016 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID732016 | Inhibition of MMP13 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID731524 | Inhibition of MMP1 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID732015 | Inhibition of MMP2 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID731523 | Inhibition of MMP12 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID107183 | Inhibition of human Matrix metalloprotease-2 | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions. |
| AID731526 | Inhibition of MMP9 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID732014 | Inhibition of MMP3 (unknown origin) | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Sulphonamides: Deserving class as MMP inhibitors? |
| AID493017 | Wombat Data for BeliefDocking | 2000 | Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2 | Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||